Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 3Gynecologic 3Head & Neck 2Breast 2Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 12Colorectal Neoplasms 8Lung Neoplasms 7Ovarian Neoplasms 6Neoplasms 5Mesothelioma, Malignant 5Carcinoma, Renal Cell 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Merkel Cell 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Pleural Effusion, Malignant 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma of Lung 2Uveal Melanoma 1

Interventions

pembrolizumab 39Gemcitabine 30Nivolumab 15Cetuximab 13Carboplatin 13Cyclophosphamide 12Cisplatin 12Irinotecan 10Docetaxel 10130-nm albumin-bound paclitaxel 10Trastuzumab 8Magnetic Resonance Spectroscopy 8fludarabine 7aldesleukin 7Paclitaxel 7Drug Therapy 7Bevacizumab 7Taxes 6Specimen Handling 6Fluorouracil 6Capecitabine 6Albumin-Bound Paclitaxel 6sargramostim 5Pemetrexed 5Oxaliplatin 5Ipilimumab 5spartalizumab 4durvalumab 4Standard of Care 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Interleukin-2 × Thoracic × Clear all
NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Alaunos Therapeutics

Phase 1/2 Terminated
8 enrolled 12 charts
GastrointestinalGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡